Coronavirus is disrupting biotech — but there's good news, too
The pandemic is disrupting biopharma studies and in turn, having a big impact on drug development. Addex Therapeutics and Arrowhead Pharma have both paused studies, citing Covid-19 as the reason.
But it's not all bad news in biotech, STAT’s Adam Feuerstein writes. For starters, the FDA is trying to improve matters for researchers, issuing a new guidance document saying it’s open to clinical trial modifications needed due to the virus.
And Canada’s Bellus Health — which is developing a new treatment for chronic cough — announced yesterday that it had completed enrollment for a mid-stage study. The company said the readout will take place mid-year, as previously projected.
But it's not all bad news in biotech, STAT’s Adam Feuerstein writes. For starters, the FDA is trying to improve matters for researchers, issuing a new guidance document saying it’s open to clinical trial modifications needed due to the virus.
And Canada’s Bellus Health — which is developing a new treatment for chronic cough — announced yesterday that it had completed enrollment for a mid-stage study. The company said the readout will take place mid-year, as previously projected.
.png)
No hay comentarios:
Publicar un comentario